Immunome, Inc. is planning a public offering to issue and sell $400 million of its common stock, with a potential additional $60 million option for underwriters.
The offering is being managed by a group of prominent firms, including Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC, and Guggenheim Securities.
The company's diverse portfolio includes late-clinical stage GSI, clinical-stage ROR1 ADC, and FAP-targeted radiotherapy among others.
Public Offering
Immunome plans a public offering to raise $400 million with a potential $60 million additional option for underwriters.
Offering Managers
Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC, and Guggenheim Securities are acting as the joint bookrunning managers.
Portfolio Highlights
The company's portfolio includes late-clinical stage GSI, clinical-stage ROR1 ADC, and FAP-targeted radiotherapy, as well as early-stage ADCs.
- Immunome's announcement of a significant public offering reflects confidence in its growth prospects and research pipeline.
- The involvement of reputable firms in managing the offering signals investor interest and confidence in Immunome's potential.
The proposed public offering by Immunome underscores its commitment to advancing targeted cancer therapies and expanding its research portfolio.